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Abstract
Background: Intervertebral disc degeneration is emphasized as an important cause of low back pain. Current
surgical treatment provides relief to the accompanying pain and disability but does not restore the biological
function of the intervertebral disc. NOVOCART™ Disc plus, an autologous cell compound for autologous disc
chondrocyte transplantation, was developed to reduce the degenerative sequelae after lumbar disc surgery or to
prophylactically avoid degeneration in adjacent discs.
Methods/design: This is a multicenter, randomized, controlled, clinical phase I/II combination study. A total of 120 adult
patients are allocated in a ratio of 2:1:1. Sample size and power calculations were performed to detect the minimal
clinically important difference of 10 units, with an expected standard deviation of 12 in the Oswestry Disability Index,
which is the primary outcome parameter. Secondary outcome parameters include the visual analog scale and the EQ-5D
questionnaire. Changes in physical and mental health are evaluated using the Short Form-12 (SF-12). Moreover,
radiological and functional outcomes are evaluated. The major inclusion criterion is a single lumbar disc herniation that
requires sequestrectomy. Transplantation is performed 90 days thereafter. Study data generation (study sites) and data
storage, processing, and statistical analysis are clearly separated.
Discussion: In this phase-I/II study, NDplus is being investigated for its clinical applicability, safety, and efficacy in the
repair of herniated, nucleotomized discs, and of adjacent degenerated discs, if present. To date, autologous disc
chondrocytes have not been transplanted into degenerative discs without previous disc herniation. As such, this is the
first study to investigate a therapeutic as well as a prophylactic approach to treat degenerative discs of the lumbar spine.
Trial registration: EudraCT No: 2010-023830-22, ID NCT01640457, 8 November 2010
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Background
The vast majority of low back pain (LBP) is self-limited or
successfully treated conservatively, whereas a small pro-
portion of patients develop chronic LBP intractable to
nonsurgical treatments. These patients present an increas-
ing medical and socioeconomic problem [1]. Interverte-
bral disc degeneration (IVDD) is emphasized as an
important cause of LBP [2, 3]. With progressive degener-
ation, the effectiveness of the nutrition mechanism of the
intervertebral disc decreases; in consequence, the nucleus
pulposus cells lose their ability to produce proteoglycan
and other important extracellular matrix proteins, which
results in disc desiccation and progressive instability [4].
Most treatment approaches, for example, the aggressive
removal of the pathological disc or spondylodesis, do not
address options of restoring structural or biological deteri-
orations when IVDD is the underlying problem. However,
cell retransplantation and restoration, as a procedure used
in this trial, would offer a less invasive and biological alter-
native to lumbar fusion in an attempt to obviate the LBP
associated with IVDD earlier in the degenerative cascade.
Until now, an intervertebral disc may only be repaired
biologically after a herniation through the transplantation
of the patient’s disc chondrocytes [5–8].
Results of the application of ADCT showed that cellu-
lar revitalization of the intervertebral disc is possible [8],
and the results of a prospective randomized and con-
trolled multicenter trial for ADCT were promising [9].
For the survival and the adaptation of the cultivated cells
to the harsh environment in the disc space, the availabil-
ity of nutrients, the number of injected cells required to
avoid nutritional problems due to cell overpopulation,
and the pro-inflammatory environment play a crucial
role. These problems should be overcome with a suitable
biomaterial, which is used in this study [10].
By using an initially liquid biomaterial, which polymer-
izes after being injected, the cells adhere much better to
the disc tissue. NOVOCART™ Disc plus (NDplus), an
autologous cell compound for autologous disc chondro-
cyte transplantation (ADCT), was developed to provide
rehydration and maintain the biological integrity of de-
generative lumbar discs to prevent secondary diseases
such as recurrent lumbar disc herniation, osteochondro-
sis, or segmental instability. The important properties of
NDplus are anti-inflammatory, antiangiogenic and anti-
osteogenic. Moreover, NDplus is hydrophilic, supports
cell morphology, and stabilizes the chrondrogenic
phenotype.
In this phase-I/II study, NDplus is being investigated
for its clinical applicability, safety, and efficacy in the re-
pair of herniated, nucleotomized discs and of adjacent
degenerated discs, if present.
The objective of this clinical study is to provide the
basis for a confirmatory study design (endpoints and
methodologies) (phase II) and to develop a safety profile
for the surgical procedure as well as for NDplus (phase
I). This study further aims at developing and validating
known and new biologic markers for the quality and
clinical efficacy of NDisc plus as requested in the con-




The NOVOCART™ Disc study is a nonconfirmatory,
prospective, multicenter, unmasked, randomized study
with two phases aimed at gathering preliminary clin-
ical information on NOVOCART™ Disc plus and
NOVOCART™ Disc basic used in the treatment of a
herniated disc. Phase I aimed to develop a safety pro-
file of the investigational medicinal product NOVO-
CART™ Disc plus. The objectives of phase II are
mainly to provide a basis for a confirmatory clinical
trial design and proof of concept. Twelve trial sites
are planned to participate in this combined phase-I/II
study; three of them have already participated in
phase I. In total, 120 patients meeting the inclusion
criteria will be randomized, treated according to the
randomization, and followed up for 5 years. The pri-
mary study endpoint of the phase II is the difference
in the Oswestry Disability Index (ODI) between treat-
ment groups 2 years after the intervention. This index
has emerged as the most commonly recommended
condition-specific outcome measure for spinal disor-
ders. It is a self-administered questionnaire divided
into 10 sections designed to assess the limitations of
various activities of daily living [11, 12]. The Short
Form-36 (SF-36) questionnaire and EuroQuality of
Life-5 Dimension (EQ-5D) are applied to assess
changes in health status and quality of life [13, 14].
Moreover, changes in leg and back pain are assessed
by the Visual Analog Scale (VAS) [15]. Numerical
measurements in the disc height, volumetry, and sig-
nal intensity of index and adjacent discs and categor-
ical evaluations, such as degeneration scale and the
presence or absence of stenosis, are determined by
magnetic resonance imaging (MRI). Neurological and
functional status and the quantity of current pain
medication and time to return to work after surgery
are documented. The serology of HIV, hepatitis and
Treponema palladium are determined preoperatively.
Laboratory values (IL-6, Leukotriene, and CRP) as
safety vales are being evaluated only in phase I of the
study. Adverse events and serious adverse events are
documented. Histological investigation of the
explanted tissue is performed. Primary and secondary
outcome parameters are outlined in more detail in
Table 1.
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Trial organization, registration, and ethical aspects
Ethics approval was attained in Germany from the
National Physician Board, “Landesärztekammer”
Sachsen-Anhalt and in Austria from the committee of
the Medical University Innsbruck. Furthermore, the
clinical trial approval was obtained from the Paul-Ehrlich-
Institute (Langen, Germany) and the Austrian Agency for
Health and Food Safety (Vienna, Austria). The ethical
bodies that approved the study in the various centers are
listed in Table 2.
The study complies with the World Medical Association
Declaration of Helsinki Ethical Principles for Medical Re-
search Involving Human Subjects, Good Clinical Practice
(GCP), national pharmaceutical acts in the participating
countries (Austria and Germany), and European guide-
lines for the conduct of clinical trials with medicinal prod-
ucts for human use. The trial is initiated and sponsored by
TETEC Ag (B|Braun Aesculap AG shared company,
Reutlingen, Germany), which is responsible for manage-
ment and registration (EudraCT No: 2010-023830-22, ID
NCT01640457). CenTrial GmbH (Tuebingen, Germany)
is responsible for clinical trial submission, independent
clinical monitoring, and pharmacovigilance. Mediri
GmbH (Heidelberg, Germany), as a core imaging lab, is
responsible for the development of the MRI protocols,
data storage and analyses. Laboratory values are investi-
gated centrally by Synlab Services GmbH (Synlab MVZ,
Leinfelden-Echterdingen, Germany). Accovion GmbH
(Eschborn, Germany) is responsible for data management,
biometrics, and medial writing. Quality assurance is being
done in cooperation with participating clinical research
organizations (CRO).
Study population
The N-Disc trial aims to include patients who qualify for
lumbar sequestrectomy because of a lumbar disc hernia-
tion. The target population consists of patients with
symptomatic lumbar disc herniation who failed adequate
conservative or interventional treatment approaches in
Table 1 Primary and secondary outcome parameters
Primary outcome parameter Oswestry Disability Index (ODI), German and Austrian version, at 5 years’ follow-up to
measure degenerative lumbar disc-related disability. [11, 12]
Secondary outcome parameter Changes in health status and quality of life will be captured by the Short Form-36 (SF-36)
version 2.0 questionnaire [14] and EuroQuality of Life 5-Dimension-3 L (EQ-5D-3 L) questionnaire [13]
Pain relief, as defined by improvement on 100 mm visual analog scale for back and leg pain [15].
Index level and adjacent disc on magnetic resonance imaging (MRI)
• by evidence of disc degeneration (Pfirrmann Classification) or osteochondrosis (Modic Changes) [30–32]
• by numerical measurements in disc high, volumetry, and signal intensity
• by T2 relaxation
• by the presence or absence of stenosis.
Pain medication usage will be assessed by a four-level score (0 = none to 3 = high level of usage).
Work status and time to return to work
Neurological status will be evaluated using the Jenny Scale as a neurological test for the lower
extremities, including motor and sensory deficits, reflexes, sciatic stretch ability and walking range.
Functional status:
• by posture and gait
• by finger-ground distance
• by Schober’s sign
• by precision tenderness/pressure pain
Table 2 Ethical bodies of the various centers
Study site Ethical body
Innsbruck Committee of the Medical University Innsbruck
Speising Committee of the Medical University Vienna
Halle National Physician Board Sachsen-Anhalt
Murnau National Physician Board Munich
Münster National Physician Board Westfahlen-Lippe
Kiel Committee of the Medical University Kiel
Karlsruhe National Physician Board Baden-Württemberg
Berlin National Physician Board Berlin
Göttingen Committee of theMedical University Göttingen
Idar-Oberstein National Physician Board Mainz
Düsseldorf Committee of the Medical University Düsseldorf
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accordance with the guidelines of DGNC and DGOOC.
Additionally, an MRI-determined lesion at treatment
level needs to correlate with the primary symptoms. To
minimize risk factors, patients with significant comor-
bidities have been excluded from the study. Written in-
formed consent has been obtained from each patient.
Inclusion and exclusion criteria are outlined in more de-
tail in Table 3.
Timetable
The visit plan is outlined in Fig. 1. In phase I, close
monitoring of the safety parameters and additional as-
sessment of the MRI will occur.
Investigational medicinal product
NOVOCART™ Disc plus (NDisc), an autologous cell com-
pound for ADCT, was developed to provide rehydration
and maintain the biological integrity of degenerative lum-
bar discs to prevent secondary diseases such as recurrent
lumbar disc herniation, osteochondrosis, or segmental
instability. NDisc plus is an injectable, in situ-
polymerizing, modified albumin, hyaluronic acid gel
with ex vivo-expanded autologous disc derived chon-
drocyte cells as the active ingredient. NDisc plus is
composed of two components: Component A is a
suspension with 3.6 to 4.4 million autologous inter-
vertebral disc cells contained in a solution of modi-
fied human albumin, human serum, culture media
components, chondroitin sulfate, and hyaluronic acid.
The total volume is 4 ml suspension placed in a 6 ml
glass vial. Component B is a bis thio-polyethylene gly-
col (BTPEG) solution; the total volume is 1 ml in a
2 ml glass vial. Components A and B polymerize in
situ using a dedicated application system (special
dual-chamber syringe) to form the desired hydrogel.
The preparation is for single use during the ADCT.
The dosage is individual, and the volume of injection
is, depending on the capacity of the treated disc, be-
tween 0.5 and 2 ml cell suspension volume. NDisc
basic is used as the placebo in the NDisc study and
is the cell-free hydrogel carrier material with an iden-
tical composition but without growth factors.
Sequestrectomy
Surgery is performed by two trial-designated surgeons
with the assistance of an operating microscope while
the patient is under general endotracheal anesthesia
and in a prone position. Depending on the location
of the disc herniation, the spinal canal harboring the
sequestrated disc material is exposed by either a min-
imal interlaminar fenestration or a translaminar ap-
proach [16]. In case of a lateral lumbar disc
herniation, a lateral extraforaminal approach is per-
formed [17]. Immediately after extraction, the disc
tissue is transferred into a sterile transport vial and
provided to TETEC AG for the GMP compliant
manufacturing of the investigational medicinal prod-
uct NDisc.
Adjacent disc disease
The presents or absence of an adjacent degenerative disc
is thought to be a potential factor affecting the prophy-
lactic treatment capacity of NDisc plus. Analyses of pri-
mary and secondary efficacy variables will be performed
separately for these two patient subgroups in addition to
the overall analysis.
Transplantation
Transplantation is performed 90 days after sequestrec-
tomy. N Disc plus (NDplus) or N Disc basic (NDbasic)
is applied via an injection with a dual-needle technique
directly at the intended site of action. NDplus or NDba-
sic is to be transplanted in a comfortable lateral or ab-
dominal position. After the treatment level is localized
and local anesthesia is performed, the puncture of the
intervertebral disc concerned takes place contralaterally
to the disc surgery. An injection needle is placed in the
center of the disc space under image guidance, and the
medicinal product is injected. In case of an ADD (adja-
cent disc degeneration), positioning of the needles and
the mandrin takes place simultaneously to minimize ra-
diation exposure (Fig. 2).
Randomization
Randomization is performed intraoperatively by enve-
lope and separately for phase I and phase II of the
study. In phase I, 24 patients are randomly assigned
to NDplus and NDbasic in a 1:1 allocation ratio. In
phase II, 96 patients are randomly assigned to
NDplus, NDbasic or follow the standard of care
treatment (surgery only, SC). The allocation ratio in
phase II is 2:1:1. Altogether, 60 patients will be
assigned to NDplus, 36 to NDbasic, and 24 to SC
(Fig. 3). Two randomization schedules are generated
by CROs using Rando™ (CRO’s proprietary
randomization software). The randomization schedule
is kept at the CRO by the randomization code ad-
ministrator, who is independent from the study team.
A copy of the randomization schedule is provided to
TETEC AG.
Sample size and power calculation
The sample size calculation is based on the primary
endpoint of the study, which is the group difference
in the ODI. A change of 10 units is considered as a
clinically meaningful difference. Moreover, a standard
deviation of 12 is assumed, based on results of a pre-
vious trial (Hägg, Fritzell, Nordwall, 2003). A sample
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Table 3 Inclusion and exclusion criteria
Initial inclusion criteria A disc herniation with back and/or leg pain (radicular pain)
Indication for sequestrectomy according to the guidelines of German Society of Neurosurgery and the German
Society of Orthopedics and Orthopedic Surgery
Age between 18 and 60 years
Physically and mentally able to participate in the study and able to understand the study, its goals,
and the possible risk factors involved
Willing and able to participate in the follow-up visit plan at the study site and able to understand and
to complete a study-relevant questionnaire in German language
Sufficiently informed about this trial orally and in writing. She/he had enough time for consideration, is
willing to participate in the study, and gives her/his written informed consent
No participation in a clinical study 90 days prior to study inclusion. She/he agrees to refrain from participating
in another clinical study during the NOVOCART™ Disc Study and for another 90 days after
study termination
Initial exclusion criteria Previous surgery at the lumbar level(s) and has been treated with NOVOCART™ Disc plus or NOVOCART™
Disc basic
Recurrent disc herniation treated with nucleotomy/sequestrectomy of the relevant disc
Degenerative muscular or neurological conditions that would interfere with evaluation of outcome measures,
including but not limited to Parkinson’s disease, amyotropic lateral sclerosis, multiple sclerosis, muscular dystrophy,
and myelopathic diseases of different causes
Body Mass Index?>?35 kg/m2
Current or recent history of illicit drug, nicotine (more than 20 cigarettes per day) or alcohol abuse or dependence
CRP?>?10 mg/dl
Pregnant, breastfeeding or planning to become pregnant. Female patients must be either at least 2 years
postmenopausal or using one of the following means of birth control during the treatment phase, that is, for
transplantation
• surgical sterility
• double barrier methods, for example, condom or diaphragm in combination with spermicide
• intrauterine contraceptive device
• bilateral vasectomy of sexual partner at least 90 days prior to enrollment in combination with barrier methods
(for example, condom or diaphragm)
• birth control pill
History of known allergies or a suspicion of allergies to any of the NOVOCART™ Disc plus or basic product
components, including hyaluronan, polyethylene glycol or albumin
Immune defects or the affinity for infections of known or unknown causes
Active systematic or local microbial infection, eczematization, or inflammable skin alterations at the site of surgery
Unable to undergo magnetic resonance imaging
History or suspicion of a disease with chronically inflammable character, as rheumatoid arthritis, gout, pseudo-gout,
metabolic bone diseases, Crohn’s disease, ulcerative colitis, lupus erythematosus, or other autoimmune disorders
Known osteoporosis
Primary hyperparathyroidism or hyperthyroidism, chronic renal failure, or previous fragility fractures
Systematic connective tissue or collagen disease
Hereditary ocular degeneration with unclear diagnosis, retinopathies based on connective tissue-defined causes,
macular corneal dystrophy
Immune suppression
History of blood coagulation disease of different genesis, including known hemorrhagic diathesis of unknown cause
Chemo or radiotherapy within the past 5 years or had any cancer other than nonmelanoma skin cancer treated with
curative intent within the past 5 years
Known diabetes, drug treated
Ulterior concomitant diseases or functional impairments of specific organs, which exclude study participation by the
assessment of the investigator
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size calculation was performed based on a two-group
t-test (nQuery Advisor™ Software, version 7.0). The
width of the respective confidence intervals were cal-
culated using a large sample approximation, with 60
patients to be enrolled in the NDplus group, 36 pa-
tients in the NDbasic group, and 24 patients in the
SC arm (120 patients in total). A detailed power cal-
culation is shown in Table 4.
Statistical analysis
Efficacy variables
The analysis of efficacy variables will focus on estimation
of treatment effects and differences between treatment
groups. For this purpose, it is assumed that effects of
treatment with SC, NDbasic, and NDplus are additive so
that treatment effects can be assessed by location shifts
(like mean change or median change) between treatment
groups. Differences between NDbasic and SC are the
total effect of NDbasic, the transplantation/implantation
procedure to inject the NDbasic, and the time interval
between tissue harvest and transplantation/implantation.
Observed differences between NDplus and SC are the
total effect of NDplus, the chondrocytes, the transplant-
ation procedure to inject the NDplus, and the time
interval between tissue harvest and cell transplantation.
Consequently, observed differences between NDplus and
NDbasic are assumed the sole effect of chondrocytes. All
efficacy data will be presented for patients in the Full
Analysis Set (FAS). Primary and secondary efficacy vari-
ables and their changes from baseline will be summa-
rized by treatment group. An analysis of variance with
factors treatment and the presence or absence of a de-
generative adjacent disc (ADD/HD) will be used to
evaluate continuous and quasi-continuous, approxi-
mately normal data. Confidence intervals will be based
on estimated means (least square means) and the corre-
sponding t-statistic. Additional covariates, such as base-
line measurements, will be included in the model as
Table 3 Inclusion and exclusion criteria (Continued)
Radiological inclusion criteria Single level lumbar disc herniation
More than 50 % remaining disc height in the herniated disc in comparison to unaffected discs in the lumbar spine. If
all discs show degenerative signs, disc height must be at least 5 mm
No obvious signs of osteophytes and no endplate sclerosis in the lumbar segment to be treated with NOVOCART™
Disc plus or NOVOCART™ Disc basic
Patients without adjacent degenerative discs (HD): adjacent proximal disc has no degenerative signs according to
Pfirrmann Score stage 3 to 5
Patients with adjacent degenerative discs (AAD): additional degenerative signs in the proximal adjacent lumbar level
according to Pfirrmann 3 to 4 but no more than 25 % disc height reduction
Radiological exclusion criteria Degenerative changes in the lumbar spine as determined by Modic Changes 2 to 3
One or more dysplastic vertebral bodies within the lumbar spine
Sacralized lumbar vertebra LWK 5 at the level to be treated with NOVOCART™ Disc plus or NOVOCART™ Disc basic
Previous or acute spondylodiscitis
Segmental instability (spondylolisthesis?>?5 mm) or translation?>?3 mm
Isthmic spondylolisthesis, ankylosing spondylitis, or spondylolysis
Lumbar scoliosis (>11° deformation)
Previous trauma, discography or any other surgical intervention at the lumbar spine
Previous compression or burst fracture at the level(s) to be treated with NOVOCART™ Disc plus or NOVOCART™ Disc basic
Central spinal canal stenosis with evidence of a narrowing of?<?8 mm (by sagittal MRI)
Spinal tumor
Metabolic bone disease
Facet ankylosis or severe facet degeneration
Lumbar kyphosis
Intra-surgery exclusion criteria Extensive damage of annulus, which subsequently poses a significantly greater risk of recurrence
Exclusion criteria after
sequestrectomy
HIV, Treponema pallidum, active hepatitis B or C infection
Exclusion criteria prior
transplantation
Recurrent disc herniation after surgery and prior transplantation
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appropriate. VAS readings will be summarized by treat-
ment group and visit over the course of the study. MRI
parameters and variables to assess functional neuro-
logical status will be summarized descriptively. Survival
analysis will be used to evaluate time to return to work
after surgery. The Kaplan-Meier product-limit estimator
will be used to estimate the probability to return to work
over time by treatment group for all patients in the FAS.
Imputation of missing data has not been planned.
Safety variables
Adverse events (AEs) will be coded according to the lat-
est Medical Dictionary for Regulatory Activities (Med-
DRA™) version available at the day of database closure.
The analysis of adverse events will focus on treatment-
emergent adverse events (TEAE). The frequency and
percentage of TEAEs and possibly related TEAEs (that
is, any possibly, probably, or definitely related TEAEs)
will be summarized according to primary system
organ class and preferred term and tabulated by treat-
ment group. All laboratory values will be classified as
normal or abnormal according to the laboratories’
normal ranges. Morphological parameters like the
Modic Score, the detection of an extra discal fluid
collection and re-herniation of the treated disc will be
monitored by a MRI protocol. An independent data
safety monitoring board (DSMB) has reviewed the phase I
data, and no concerns have been raised. An ongoing
Fig. 1 Visit plan. In phase I, close monitoring of the safety parameters and an additional assessment of the magnetic resonance imaging (MRI) will occur
Fig. 2 Transplantation. An injection needle is placed in the center of the disc space contra-laterally to the side of the disc surgery. In case of an
adjacent disc disease, positioning of the needle takes place simultaneously to minimize radiation exposure
Tschugg et al. Trials  (2016) 17:108 Page 7 of 10
evaluation by the DSMB will be undertaken during phase
II. If relevant concerns should be detectable like increased
reherniation rates, a discontinuation of the trial must be
considered.
Interim and final analysis
Data collected in the study may be analyzed and
reviewed continuously. Early findings may be used to
stop the study in case of safety concerns or lack of
efficacy or futility with regard to a positive outcome
in the NDplus group. To ensure the efficient use of
clinical data, interim analyses are being performed
(see Table 5).
Discussion
Next to the high prevalence of lumbar back pain caused
by degenerative disc disease and the increasing number
of spinal interventions [1], the major advantage of disc
repair procedures is the ability to address the source of
low back pain with a minimally invasive technique. Au-
tologous chondrocyte cell transplantation has been
shown to reduce intervertebral disc degeneration in ani-
mal models, as well as to be safely applicable in humans
[9, 18, 19].
The avascularity of the lumbar disc is a promising pre-
condition for autologous chondrocyte cell transplant-
ation. Limited blood flow inhibits cell migration and
provides an immunologically privileged environment
[20]. Controversially, transplanted cells must survive in a
limited blood supply and in a mechanically stressful en-
vironment that can cause a loss of native chondrocyte
cells and leads to a decreased extracellular matrix pro-
duction [4]. Therefore, the choice of biomaterial is
important.
By using an initially liquid biomaterial, which poly-
merizes after being injected into the intervertebral
disc, the cells adhere much better to the disc tissue.
In an animal experiment, a significant increase in the
survival rate of cells that were injected into the inter-
vertebral disc was achieved with a polymerizing bio-
material as opposed to the application in a watery
solution [10].
The use of hyaluronic acid and chondroitin sulfate
in a defined concentration and composition stabilizes
the phenotype of the expanded cells and allows an
environmental conditioning, a more balanced nutrient
distribution, and ultimately a higher cell survival rate
after transplantation, by anti-inflammatory and os-
motic effects [21–23]. Furthermore, the polymerizing
hydrogel has anti-osteogenic and anti-angiogenic ef-
fects [24].
Fig. 3 Randomization. Randomization is performed separately for
phase I and phase II of the study
Table 4 Power calculation
Treatment group mean /
Treatment effect (contrast)
Width of two-sided 95 % confidence interval from point esti-
mate to limit (units in standardized ODI)
Power of pairwise t-test to detect a difference
in change from baseline of 10 units in ODI
ODI sum score
(SD = 12 points)
Change in ODI (SD = 14.7 points = 12*sqrt
(2(1-r))when r = 0.25
Change in ODI (SD = 14.7 points = 12*sqrt
(2(1-r))when r = 0.25
SC (n = 24) 4.80 5.88 –
NDbasic (n = 36) 3.92 4.80 –
NDplus (n = 60) 3.04 3.72 –
NDbasic (n = 36) versus SC (n = 24) 6.20 7.59 71 %
NDplus (n = 60) versus SC (n = 24) 5.68 6.96 79 %
NDplus (n = 60) versus NDbasic (n = 36) 4.96 6.07 89 %
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The hydrodynamic properties of hyaluronic acid
have been known for many years [25]. Glycosamino-
glycan plays a major role in the extracellular matrix
of the healthy human intervertebral disc [26]. In an
intervertebral disc with degenerative changes, how-
ever, the proteoglycans, the level of hyaluronic acid,
and subsequently, the fluid content are already sub-
stantially reduced [27, 28]. Besides a high bio- and
cell compatibility, a polymerizable biomaterial must
also possess other important properties in order to
be suitable for the biological disc reconstruction. It
must ensure that the biomaterial stays in the disc
after its in vivo polymerization and during the remo-
bilization of the patient, that is, during increased
physical stress [29].
The goal of ADCT is to reduce the degenerative se-
quelae after lumbar disc surgery or to prophylactically
avoid degeneration in adjacent discs. Injection of ma-
terial into the disc, however, theoretically carries sev-
eral risks, such as extrusion of the injected material,
increased intradiscal pressure, potentially provoking
disc herniations, and local or systemic inflammatory
reactions.
Trial status
Phase I of the trial started in October 2012 with one
site in Austria (the Department of Neurosurgery,
Medical University Innsbruck), followed by two sites
in Germany (the Department of Neurosurgery, BG
Clinic Halle-Bergmannstrost (February 2013) and De-
partment of Neurosurgery, BG-Clinic Murnau (March
2013)). Phase I revealed no relevant safety issues as
reviewed by an independent DSMB. Thus, phase-II
was planned with the following nine sites in
Germany and Austria contributing: the Department
of Neurosurgery, Medical University Düsseldorf; De-
partment of Orthopedics-II, St. Franziskus Hospital
Muenster; Department of Neurosurgery, Medical Uni-
versity Charité Berlin; Center of Spine Surgery, DRK
Clinic Berlin Westend; Department of Neurosurgery,
City Clinic Karlsruhe; Department of Neurosurgery,
SHG Clinic Idar-Oberstein; Department of Trauma
Surgery, Medical University Göttingen; Department
of Neurosurgery, Medical University Schlewig-
Holstein (Kiel); and Department of Spine Surgery,
Orthopedic Hospital Speising.
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Table 5 Interim and final analyses
1st interim analyses Early evaluation for safety and feasibility, when all 24 patients of phase I are randomized
and tissue explants, implant procedures, and 6-week follow-up visits are completed.
2nd interim analyses Final evaluation for surgical feasibility of the procedures, when all enrolled patients have
completed the sequestrectomy and transplantation.
3rd interim analyses Early evaluation for efficacy with patients who have completed the 12-month follow-up visit.
4th interim analyses Primary evaluation for efficacy with all patients who have completed the 24-month follow-up visit.
Final analyses When all patients have completed the scheduled 60-month follow-up visit.
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